Topic

GLP-1s & Cardiometabolic Health.

Semaglutide (Wegovy, Ozempic), tirzepatide (Mounjaro, Zepbound), and the pipeline behind them are reshaping cardiometabolic care faster than the system can absorb. Dr. Runge writes on what's evidence and what's marketing — and on the access and cost questions the headlines tend to skip.

What's actually changed

Cardiovascular outcomes data — not just weight loss — is now part of the conversation. The SELECT trial showed semaglutide reduces major adverse cardiovascular events in non-diabetic patients with obesity and existing CV disease. That's a structural shift in cardiology, not a fad.

The questions that haven't been answered

Long-term maintenance: what happens at year 5, year 10, when patients stop?
Lean-mass loss and sarcopenia in older patients
Cost: $1,000+/month retail prices, partial insurance coverage, and what that means for population-level deployment
Compounded versions: legality, safety, and the FDA's evolving stance

Where to read more

Stay close to this thread.

Be first to know when The Longevity Switch Substack and the Michigan MOOC launch. One email, no spam.